The Dutch healthcare institute has called out drug manufacturers for allegedly withholding information. A spokesperson for Gilead told Euractiv they already submitted a comprehensive dossier.
A new drug reimbursement principle is seen as a significant departure from value-based pricing. Despite concerns, the new pricing system could increase the availability of some orphan drugs by 35 per cent.
From energy and trade to finance and defense, here’s how Donald Trump’s second presidency will impact EU policy.
If Kamala Harris wins the election, she will likely approach the task of filling out her Cabinet and West Wing much like she did when she took over Joe Biden’s campaign operation this summer. While she’ll ensure her closest advisers and key Cabinet members are people she personally trusts, there will be some continuity with […]
Despite calls to step up efforts, investment in antimicrobial resistance is still insufficient.
Sweden favours creating a compulsory rule for companies to apply for medicines pricing and reimbursement in any member state requesting it. A minority of EU countries currently support this approach, but pharma package talks continue.
Novo Nordisk has denied U.S. president’s claim it is “ripping off” consumers, saying the reality isn’t so simple.
Lower drug pricing does not follow from an expansion of innovative medicine indications, according to Dutch researchers. They claim pharma companies often fail to pass on their financial gain to patients and health services.
The European Commission has open infringement procedures against Bulgaria for the long-term violation of internal market rules and illegal procedures allowing private hospitals to avoid tendering for medicines.
While DNA-altering treatments promise to cure many rare diseases, they might not qualify for planned bonuses.
The Bulgarian government should focus on ensuring timely and equitable access to innovative therapies for Bulgarian patients while preserving the financial sustainability of the national drug pricing and reimbursement system, the executive director of …
The romantic relationship between Pernille Weiss and Christian Ehler has raised questions about why an independent study was taken offline.
A European Parliament study that centers on the delicate topic of incentives for drug companies was published, then pulled offline again, pending further queries from MEPs.
The EU wants to steer drug development to cover research gaps, but industry hates the idea.
Not all patients are equal when it comes to treatment with cutting-edge drugs.
A major drug pricing crackdown in the US is threatening drug companies’ bottom lines.
The disproportionate intellectual property protections the bloc proposes could threaten the affordability of generics that countries like India and Indonesia export to poorer nations.
Good intentions don’t necessarily translate to good policy, and the bloc’s proposal will make it harder for companies to conduct research and for Europeans to reap the benefits of cutting-edge drugs.
Governments can and must take control to prevent extreme drug prices.
